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Organizationa b s t r a c t
ESTRO surveyed European radiation oncology department heads to evaluate the impact of COVID-19.
Telemedicine was used in 78% of the departments, and 60% reported a decline in patient volume. Use
of protective measures was implemented on a large scale, but shortages of personal protective equipment
were present in more than half of the departments.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 150 (2020) 40–42 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).The recent outbreak of the novel coronavirus SARS-CoV-2, lead-
ing to COrona VIrus Disease 19 (COVID-19), has a large impact on
the provision and organization of cancer care [1,2]. Cancer patients
represent one of the most fragile groups due to their sometimes
compromised clinical conditions and ongoing treatments. For
patients undergoing or planned for radiation therapy, radiation
oncology (RO) departments adjusted management protocols to
maintain their ability to deliver optimal care to all of their patients.
In the past three months, numerous articles, case-reports and edi-
torials were published to address these issues in general or for
specific disease sites or treatment modalities [3–6].
The American Society for Radiation Oncology (ASTRO) surveyed
over 500 physician leaders of US departments to understand the
impact of the pandemic and the changes that have been imple-
mented to cope with them [7]. The ASTRO leadership offered theEuropean SocieTy for Radiotherapy and Oncology (ESTRO) to use
this questionnaire as a basis for a European survey. The question-
naire, slightly modified to be used by ESTRO, was sent on May 6,
to 474 ESTRO members who were registered as head of a radiation
oncology (RO) department in Europe plus 26 representatives of
other departments with no registered head. After 14 days a total
of 139 (nearly) completed questionnaires were received (response
rate 28%) from 29 different countries. Most responses were from
Italy (20; 14%), Germany (17; 12%), Spain (15; 11%), the Nether-
lands (10; 7%), Switzerland (9; 6%), the United Kingdom (8; 6%)
and Belgium (7; 5%). The remaining 53 represented less than 5%
of all responses and were from the 22 other countries.
Responding departments treat a median of 1300 new cancer
cases annually (range: 100–6500); with staffing levels being at a
median of 9 FTE radiation oncologists (range: 1–43) and 18 FTE
radiation technologists (range: 4–144). During the pandemic, the
median number of patients under treatment was 100 per day
(range 6–440).
All departments were operational. In 58% of them, treatment of
some new patients was deferred to a later date. As shown in
Table 1, this varied from 40% in Italy and the Netherlands to
100% of the responding centers in the United Kingdom.
In 78% of the departments (109), telemedicine was used, being
specifically introduced now in 83 of them (76%). Telemedicine was
used for clinical assessment of patients under treatment in 22% of
the departments and for surveillance visits during follow-up in
Table 1
Use of telemedicine for patients under treatment and for follow-up, deferral/delay of some patient groups, observed decline in number of patients, and causes for shortage of staff.
Country Telemedicine Deferring Decline in Staff shortage
Under
treatment
Follow-up patients number of
patients
Covid disease Family care Fewer
patients
Staff transfer
Italy 1/20 5% 14/20 70% 8/20 40% 12/20 60% 8/20 40% 7/20 35% 1/20 5% 4/20 20%
Germany 2/17 12% 7/17 41% 13/17 76% 9/17 53% 1/17 6% 3/17 18% 1/17 6% 1/17 6%
Spain 4/15 27% 13/15 87% 11/15 73% 8/15 53% 10/14 71% 4/14 29% 2/14 14% 4/14 29%
Netherlands 6/10 60% 10/10 100% 4/10 40% 5/10 50% 0/9 0% 2/9 22% 1/9 11% 2/9 22%
Switzerland 4/9 44% 7/9 78% 8/9 89% 5/9 56% 1/9 11% 2/9 22% 0/9 0% 1/9 11%
United Kingdom 7/8 88% 6/8 75% 8/8 100% 7/8 88% 5/7 71% 5/7 71% 0/7 0% 2/7 29%
Belgium 0/7 0% 7/7 100% 3/7 43% 6/7 86% 2/6 33% 0/6 0% 2/6 33% 0/6 0%
Other 7/53 13% 36/53 68% 26/53 49% 32/53 60% 8/52 15% 16/52 31% 8/52 15% 4/52 8%
All 31/139 22% 100/139 72% 81/139 58% 84/139 60% 35/134 26% 39/134 29% 15/134 11% 18/134 13%
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highest use of telemedicine in the United Kingdom and the Nether-
lands (Table 1).
A decline in patient volume was noticed in 60% of the depart-
ments. This was due to delays/deferrals for certain disease sites
in 65%, reduced referrals in 75% and shortage of staff in 15%. The
reduction in patient volume was on average 25% (median 20%),
with an ensuing estimated decrease of >20% in revenue reported
by 25% of the departments. As shown in Table 1, the decline was
more often reported in centers from Belgium and the United
Kingdom.
A reduction in staff occurred in 57% of the departments, mainly
due to the impact of the COVID-19 pandemic on family care
responsibilities (29%), staff COVID-19 illness (26%) and staff trans-
fer to other clinical areas (13%). In 11%, staffing was reduced due to
the smaller number of patients visiting the department. In the
Netherlands, Germany and Switzerland, COVID-19 infection of staff
was infrequent, whereas it was reported in around 70% in Spain
and the United Kingdom (Table 1).
All centers were asked whether they were delaying treatment
for specific indications. The most common indications were:
 Prostate cancer (low risk 62%; intermediate risk 40%, high risk
20%).
 Non-malignant indications (38%).
 Early stage breast cancer (31%).
 Palliative nonemergent indications (25%).
 Non-melanoma skin tumors (16%).
 Low grade gliomas (16%).
 SBRT for oligometastatic disease (10%).
Protection measures in use for the staff included:
 Routine use of masks (89%).
 Social distancing (88%).
 Use of gloves (69%), face shields (52%) and/or gowns (46%) for
treatments and procedures.
 Screening prior to each shift (60%).
 Staggered shift scheduling (58%).
Screening of all patients at the entrance was performed in 82%,
and 88% of the departments didn’t allow visitors. Increased clean-
ing/disinfecting of immobilization devices was done in 95% and
increased cleaning/disinfecting of treatment tables in 85%.
Shortages of personal protective equipment were reported by
48% of the departments, of medical hand sanitizer by 20% and of
nasopharyngeal swabs for SARS-CoV-2 specimen collection in
16%. As shown in Table 2, there were important differences
between countries for the various items. Shortages of drugs were
reported by 6%. Forty-five percent reported no shortages for any
of the items.The vast majority of departments (95%) used national guideli-
nes (85%) or information from ESTRO (62%) and ASTRO (29%) web-
sites for guidance during the COVID-19 pandemic (Table 2). It
should be noted that in some countries (e.g. Belgium) the national
guideline referred to ESTRO (and ASTRO) websites.
A comparison of the European data with data from North-
America [1], shows many similarities. However, in the ASTRO
report, 84% of centers reported a decrease in patient volumes to
80% or less compared to normal, whereas this was the case in only
38% of the European centers. Similarly, a larger effect on practice
revenue was foreseen by American centers. Another important dif-
ference was the related to the availability of one or more key sup-
plies. There was a shortage in 78% of the US centers, while this was
the case in only 52% of the centers in Europe, but with large vari-
ation between countries. For reference, an overview of the
COVID-19 situation in the top-7 responding countries is given in
Table 3 [11].
The COVID-19 pandemic has created an unprecedented chal-
lenge for health care systems worldwide. Radiation therapy is a
life-saving treatment and should be guaranteed to all patients with
cancer for whom it is indicated. Limitations in resources, including
space, equipment, and staff, may result in reduction of treatment
capacity. Furthermore, exposure of high-risk patients to SARS-
CoV-2 should be minimized by limiting the number of visits for RT.
The ESTRO survey gathered responses from a large number of
RO centres (139) in a very short time period and displays an inter-
national overview of RT management during the COVID-19
pandemic.
This survey shows that, irrespective of national differences that
may partly be explained by the number of respondents and the
varying epidemiological impact of the pandemic in different Euro-
pean countries, the radiation oncology community immediately
organised itself with joint efforts to ensure continuity of therapies
while protecting patients, healthcare professionals, and the general
population.
Old principles were quickly adopted as new behaviors to Euro-
pean radiation oncologists:
SARS: Safety, Avoidance, Rescheduling, Shortening.
S: Safety, meaning use of PPE for healthcare professionals and
patients, triage for screening of patients, no visitors in RO depart-
ments, telemedicine for follow-up visits and clinical multidisci-
plinary evaluations;
A: Avoidance, meaning omission of radiation therapy when the
risk of severe complication from COVID-19 (for elderly patients
and/or with serious underlying health conditions) outweighs the
benefit of radiation therapy;
R: Rescheduling, meaning deferring/delaying of RT when there
is no or little expected adverse effect on outcome from the delay;
S: Shortening, meaning more extensive use of hypofractionated
schedules with the aim of maintaining high tumor control proba-
bility rates without undue toxicity.
Table 2
Shortage of personal protective equipment (PPE), medical hand sanitizer and nasopharyngeal swabs for COVID19 tests and use of ESTRO and ASTRO websites and/or national
guidelines.
Country Shortage of ESTRO ASTRO National
PPE Hand sanitizer Covid-swabs website website guidelines
Italy 8/19 42% 3/19 16% 4/19 21% 14/20 70% 5/20 25% 17/20 85%
Germany 13/17 76% 11/17 65% 1/17 6% 9/17 53% 4/17 24% 17/17 100%
Spain 7/15 47% 1/15 7% 0/15 0% 8/14 57% 4/14 29% 13/14 93%
Netherlands 4/9 44% 3/9 33% 2/9 22% 6/9 67% 3/9 33% 9/9 100%
Switzerland 2/9 22% 1/9 11% 1/9 11% 7/9 78% 5/9 56% 8/9 89%
United Kingdom 4/7 57% 2/7 29% 1/7 14% 1/7 14% 0/7 0% 6/7 86%
Belgium 4/6 67% 0/6 0% 4/6 67% 2/6 33% 1/6 17% 4/6 67%
Other 22/52 42% 6/52 12% 8/52 15% 36/51 71% 16/51 31% 38/51 75%
All 64/134 48% 27/134 20% 21/134 16% 83/133 62% 38/133 29% 112/133 84%
Table 3
Daily new and total COVID-19 cases and deaths in seven responding countries on May 21, 2020 [11].
Cases Deaths
Country Population (M) Daily new Total Daily new Total
Italy 60,5 642 228,006 156 32,486
Germany 83,7 490 179,021 39 8309
Spain 46,8 539 280,117 52 27,904
Netherlands 17,1 253 44,700 27 5775
Switzerland 8,7 36 30,694 6 1898
United Kingdom 67,9 2615 252,947 338 36,042
Belgium 11,6 252 56,235 36 9186
42 Effect of COVID-19 pandemic on practice in European radiation oncology centersWe should acknowledge the potential bias and selection of the
centers who responded to the survey, with the number of
responses per country not being clearly related to the number of
centers in the various countries. Additionally, the survey was a
snapshot at a certain date relatively late during the COVID-19 pan-
demic where many issues, which were present initially, had
already been resolved and written in guidelines [8,9].
As the survey did not include questions on fractionation
choices/modifications during this time of crisis, it is not able to
evaluate potential differences on shortening of treatment that
may certainly have been present at European level [10]. It did,
however, clearly document variations amongst European countries
regarding aspects linked to safety, avoidance and rescheduling.
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